BriaCell Therapeutics Corp. (BCTX)
Automate Your Wheel Strategy on BCTX
With Tiblio's Option Bot, you can configure your own wheel strategy including BCTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCTX
- Rev/Share 0.0
- Book/Share 1.1953
- PB 2.5026
- Debt/Equity 0.0
- CurrentRatio 1.3693
- ROIC -0.4179
- MktCap 19089469.0
- FreeCF/Share -8.1476
- PFCF -0.8679
- PE -0.7778
- Debt/Assets 0.0
- DivYield 0
- ROE 66.0595
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 2
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical data in three clinical poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. BriaCell has featured robust survival and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical progress data from its ongoing pivotal Bria-IMT Phase 3 study (ClinicalTrials.gov identifier: NCT06072612), and Phase 1/2 study of Bria-OTS (ClinicalTrials.gov identifier: NCT06471673) in metastatic …
Read More
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA and VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the presentation of positive survival and clinical benefit data in three clinical poster presentations and one publish-only abstract at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.
Read More
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patients Presence of Circulating Tumor Cells (CTC) after patients' initial Phase 3 treatment supports role as negative prognostic marker (p = 0.04) Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile PHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 …
Read More
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT™, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. In addition, Phase 3 early biomarker data will be presented as a late breaking abstract.
Read More
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Over 75 patients enrolled in BriaCell's pivotal Phase 3 study of Bria-IMT ™ plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is …
Read More
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR.
Read More
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer (NCT06072612) and recommended …
Read More
About BriaCell Therapeutics Corp. (BCTX)
- IPO Date 2012-03-14
- Website https://www.briacell.com
- Industry Biotechnology
- CEO Dr. William V. Williams FCPA, M.D.
- Employees 16